Extended model‐based designs for more complex dose‐finding studies
暂无分享,去创建一个
[1] Shyamal D Peddada,et al. Designs for Single‐ or Multiple‐Agent Phase I Trials , 2004, Biometrics.
[2] J O'Quigley,et al. Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method , 2011, Statistics in medicine.
[3] John O'Quigley,et al. Continual Reassessment Method for Ordered Groups , 2003, Biometrics.
[4] Bradley P. Carlin,et al. Bayesian measures of model complexity and fit , 2002 .
[5] J O'Quigley,et al. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.
[6] Sarah Zohar,et al. Retrospective Robustness of the Continual Reassessment Method , 2010, Journal of biopharmaceutical statistics.
[7] Shing M. Lee,et al. Model calibration in the continual reassessment method , 2009, Clinical trials.
[8] Ying Yuan,et al. Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials , 2009 .
[9] J O'Quigley,et al. Two-sample continual reassessment method. , 1999, Journal of biopharmaceutical statistics.
[10] Ying Kuen Cheung,et al. A Simple Technique to Evaluate Model Sensitivity in the Continual Reassessment Method , 2002, Biometrics.
[11] J O'Quigley,et al. Continual reassessment method: a likelihood approach. , 1996, Biometrics.
[12] A. Oza,et al. Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Alan E. Gelfand,et al. Model choice: A minimum posterior predictive loss approach , 1998, AISTATS.